Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

Similar articles for PubMed (Select 22986394)

1.

ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF.

Klein L.

Ann Intern Med. 2012 Sep 18;157(6):JC3-2. doi: 10.7326/0003-4819-157-6-201209180-02002. No abstract available.

PMID:
22986394
2.

New oral anticoagulants for atrial fibrillation: a review of clinical trials.

O'Dell KM, Igawa D, Hsin J.

Clin Ther. 2012 Apr;34(4):894-901. doi: 10.1016/j.clinthera.2012.01.019. Epub 2012 Mar 13. Review.

PMID:
22417716
3.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
4.

ACP Journal Club. Apixaban reduced stroke or systemic embolism more than warfarin in AF regardless of renal function.

Jones MM.

Ann Intern Med. 2012 Dec 18;157(12):JC6-7. doi: 10.7326/0003-4819-157-12-201212180-02007. No abstract available.

PMID:
23247956
5.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
6.

Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.

Deedwania PC, Huang GW.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):265-75. doi: 10.2165/11592410-000000000-00000. Review.

PMID:
21740079
7.

ACP Journal Club. Apixaban reduced stroke and systemic embolism compared with aspirin in adults with AF for whom VKA therapy was unsuitable.

Dunn A.

Ann Intern Med. 2011 Apr 19;154(8):JC4-3. doi: 10.7326/0003-4819-154-8-201104190-02003. No abstract available.

PMID:
21502641
9.

Prevention of stroke in patients with atrial fibrillation.

Olsson SB, Halperin JL.

Semin Vasc Med. 2005 Aug;5(3):285-92. Review.

PMID:
16123916
10.

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.

Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM.

Eur Heart J. 2011 Oct;32(19):2387-94. doi: 10.1093/eurheartj/ehr342. Epub 2011 Aug 28.

11.
12.

Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.

J Stroke Cerebrovasc Dis. 2012 Apr;21(3):165-73. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011. Review.

PMID:
22440950
13.

ACP Journal Club: adding renal dysfunction to CHADS2 did not improve prediction of stroke or systemic embolism in AF.

Clase CM, Zimmerman DL, A Thomson BK.

Ann Intern Med. 2013 Apr 16;158(8):JC13. doi: 10.7326/0003-4819-158-8-201304160-02013. No abstract available.

PMID:
23588766
14.

Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

Escobar C, Barrios V, Jimenez D.

Cardiovasc Ther. 2010 Oct;28(5):295-301. doi: 10.1111/j.1755-5922.2010.00216.x. Epub 2010 Aug 16. Review.

PMID:
20718760
15.

Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis.

Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L.

Heart. 2008 Dec;94(12):1607-13. doi: 10.1136/hrt.2007.135657. Epub 2008 Jan 20. Review.

PMID:
18208828
16.

Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.

Ford GA, Choy AM, Deedwania P, Karalis DG, Lindholm CJ, Pluta W, Frison L, Olsson SB; SPORTIF III, V Investigators.

Stroke. 2007 Nov;38(11):2965-71. Epub 2007 Sep 20.

17.

ACP Journal Club. Compared with warfarin, high-dose dabigatran might be cost-effective for preventing stroke in older patients with nonvalvular AF.

Masoodi NA.

Ann Intern Med. 2011 Jun 21;154(12):JC6-12. doi: 10.7326/0003-4819-154-12-201106210-02012. No abstract available.

PMID:
21690590
18.

Evaluation and management of atrial fibrillation.

Ali S, Hong M, Antezano ES, Mangat I.

Cardiovasc Hematol Disord Drug Targets. 2006 Dec;6(4):233-44. Review.

PMID:
17378769
19.

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.

Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators.

Am Heart J. 2006 Nov;152(5):967-73.

PMID:
17070169
20.

Preventing stroke in atrial fibrillation: the SPORTIF programme.

Lip GY.

Pathophysiol Haemost Thromb. 2005;34 Suppl 1:25-30. Review.

PMID:
15812201
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk